Prosecution Insights
Last updated: November 20, 2026

Erinne R Dabkowski, USPTO Patent Examiner

Listed by the USPTO as DABKOWSKI, ERINNE R

Tech Center 1600 • Art Units: 1654 1675 1683

This examiner grants 56% of resolved cases

Analysis

DABKOWSKI, ERINNE R has resolved 721 cases, with an allowance rate of 55.8% and a median of 1061 days to allowance. The substantial record indicates an allowance outcome near the middle of the reported range, with a median timeline exceeding a short prosecution cycle.

The interview lift is 68.8%, making interviews a prominent consideration for prosecution strategy. The listed companies are The Regents of the University of Michigan, The Ohio State University, and The Chinese University of Hong Kong. The listed firms are Knobbe, Martens, Olson & Bear, LLP, Casimir Jones, S.C., and Clark+Elbing LLP.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

55.8%
Allow Rate
-4.2% vs TC avg
798
Total Applications
+68.8%
Interview Lift
1061
Avg Prosecution Days
Based on 721 resolved cases, 2023–2026

Rejection Statute Breakdown

6.5%
§101 Eligibility
14.6%
§102 Novelty
29.5%
§103 Obviousness
32.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18313856 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS Final Rejection The Regents of the University of Michigan
18163773 TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS Non-Final OA THE REGENTS OF THE UNIVERSITY OF MICHIGAN
18294706 COMPOSITIONS AND METHODS FOR TREATING MASTITIS Non-Final OA Zoetis Services LLC
17782508 VEGF MINI-TRAPS AND METHOD OF USE THEREOF Non-Final OA REGENERON PHARMACEUTICALS, INC.
18428102 GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF Non-Final OA Eli Lilly and Company
19329417 CELL-PENETRATING PEPTIDE COMPOUNDS Final Rejection Ohio State Innovation Foundation
18755185 CELL-PENETRATING PEPTIDE SEQUENCES Final Rejection Ohio State Innovation Foundation
16771641 METHOD OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA (ITP) WITH ROMIPLOSTIM Non-Final OA AMGEN INC.
16954694 COMPOSITIONS AND METHODS USING A COMBINATION OF AUTOPHAGY INDUCER AND HIGH PROTEIN FOR INDUCTION OF AUTOPHAGY Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
17275764 METHODS AND COMPOSITIONS FOR TREATING SKIN DISEASES Final Rejection VANDERBILT UNIVERSITY
17925455 Methods and Compositions for Treatment of Age-Related Dysfunction Non-Final OA The University of Tokyo
16008281 FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE Final Rejection Roche Diagnostics Operations, Inc.
17247153 Methods for Inducing Intermittent Fasting and Modulating Autophagy Final Rejection The Chinese University of Hong Kong
16427593 Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities Non-Final OA The Chinese University of Hong Kong
18007323 NUTRITION FORMULATION Non-Final OA OTSUKA PHARMACEUTICAL FACTORY, INC.
17634975 PALM FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY INCIDENTAL TO THE TREATMENT OF CANCER Non-Final OA Peptinovo Biopharma Inc.
17283315 Selective Binding and Aggregation of Human Keratin in the Skin Barrier Using Human Filaggrin Subdomains SD67 and SD150 Final Rejection YALE UNIVERSITY
16617497 USE OF CITRULLINE AND GLUTATHIONE TO INCREASE MUSCLE MASS Final Rejection KYOWA HAKKO BIO CO., LTD.
18674214 Protective Agent Against Endothelial Dysfunction Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17672438 COMPOSITIONS AND METHODS FOR INHIBITING BIOFILM DEPOSITION AND PRODUCTION Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
18030174 GRIFFITHSIN FOR RHABDOVIRIDAE INFECTIONS Non-Final OA University of Louisville Research Foundation, Inc.
18697295 LIPID MEDIATOR CHAPERONE AND USES THEREOF Non-Final OA The Children's Medical Center Corporation
18685702 GDF15 FUSION PROTEINS AND USES THEREOF Non-Final OA SUNSHINE LAKE PHARMA CO., LTD.
18125007 SECRETOGLOBIN FAMILY 1D MEMBER 2 (SCGB1D2) PROTEIN INHIBITS GROWTH OF BORRELIA BURGDORFERI AND AFFECTS SUSCEPTIBILITY TO LYME DISEASE Non-Final OA University of Helsinki

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Erinne R Dabkowski's allowance rate?

55.8% of resolved applications examined by Erinne R Dabkowski were allowed (721 resolved cases), compared with 48.2% across Art Unit 1654 over the last five years.

Does an interview help with examiner Erinne R Dabkowski?

This examiner's interview lift is +68.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Erinne R Dabkowski take to allow a patent?

Applications allowed by Erinne R Dabkowski took 1,061 days on average from filing to allowance.

Which art unit does examiner Erinne R Dabkowski work in?

Erinne R Dabkowski examines applications in Art Unit 1654 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month